about
Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus.Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation.Molecular determinants of irinotecan efficacy.Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer.Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.Generation of a concise gene panel for outcome prediction in urinary bladder cancer.Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer.Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survivalGenetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer.Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabAssociation of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer.GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients.Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastasesThe Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.Primary tumor location as a prognostic factor in metastatic colorectal cancer.Influence of sex on the survival of patients with esophageal cancer.Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR ApproachVariations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancerGender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review.The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis.Genetic variants associated with colorectal brain metastases susceptibility and survival.Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
P50
Q33204657-5047B737-0A22-43E2-BA58-F5545A5D4035Q33250474-B7582053-2D03-40F4-9349-5C267246B485Q33253178-9A4929B3-F615-4DEA-8633-55F689B0D02EQ33269959-716D1F80-790B-4038-B69E-63EDDD9B3AD3Q33310747-495595BD-4E16-437F-9FA6-A386CCD6A87FQ33383830-6C0A6217-1B24-48BC-9E43-6AFB9E9AFA15Q33387793-4FA5B2F5-52EA-4AFA-BEB6-1BFE31185946Q33561596-2C6E91FC-52C3-4F77-BB27-66470B5CA116Q34137865-06D94E1E-15E3-4A1C-B0D3-984AB530F228Q34283333-8653C444-B363-422D-AD9A-883ABABA8530Q34308255-31F4CC56-EE46-4772-BDC4-108F79765049Q34349252-FFBB5D51-97EB-4058-99DD-F442029DA8A6Q34663753-E98BF295-398E-44CB-A981-81CECEF292FCQ34825323-277F1A92-0876-43BF-B1DE-D6B7617565BCQ35005752-A793CD58-DB75-4144-BDA2-8A149C68E09CQ35432445-ECEA1627-DF2A-4C25-B6A8-767133466FBEQ35637857-05E5B358-6A1A-4661-8AF2-1AF1E7A9D875Q35879070-055CAD77-9526-4A05-9A70-57400904EC51Q35988844-B745B163-A5DF-4935-AE3F-626322656E46Q36047405-03E99FF9-2819-4D53-BA75-9EAA2C6ECF43Q36097512-28241965-A04E-41D2-BFAB-70F69748B875Q36132737-515F5AC0-1247-4153-9B38-E087AB95C589Q36132835-4AE2616A-C714-4707-A70E-EA46643F1436Q36316649-CCA23F7C-4A41-41AD-8BDD-54EE1C582EB3Q36689794-4CEFF921-1529-441A-8C42-B049A735CAF2Q37075302-E6E9237A-4E29-443B-983A-2A77FD0A79E9Q37146300-742AAA7F-A870-44BC-A670-5269123EFD40Q37332789-C564E4D7-5FC2-44F3-A81A-BC26ADCF32BCQ37482521-46CE158E-88DB-4D34-A26D-70EA5CE3E3BDQ37619811-961CEC0B-44D9-45E0-AB05-A294AD6B2412Q37623740-45CE3573-13B8-4F8B-AC87-85CA77168705Q37735989-1462BB1D-12ED-4E4F-9618-30814B74C83CQ38551684-58860385-BB5E-4851-B015-8D611EF21DF2Q39385369-E2601C8C-326D-44FF-A40F-1135FA7EFE08Q39479370-8DC081AA-2132-4CE4-81D1-1846F59E1ADBQ39677535-29B206AD-C9E9-4E76-8C84-F45C68EC9A5FQ40324587-E52801B9-ECB9-495E-A2E6-3B803890F3F6Q41032563-5713CF6E-95CD-4D4A-8B7D-D6500453861AQ41265675-59D6B4B4-F8E4-440B-AB5D-6B6A41F13F80Q41714515-1FFE825B-5364-45ED-BE41-1D344D3DBFF2
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Dongyun Yang
@ast
Dongyun Yang
@en
Dongyun Yang
@es
Dongyun Yang
@nl
Dongyun Yang
@sl
type
label
Dongyun Yang
@ast
Dongyun Yang
@en
Dongyun Yang
@es
Dongyun Yang
@nl
Dongyun Yang
@sl
prefLabel
Dongyun Yang
@ast
Dongyun Yang
@en
Dongyun Yang
@es
Dongyun Yang
@nl
Dongyun Yang
@sl
P106
P1153
12772988600
P31
P496
0000-0003-0736-4977